DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Smyth LM, Piha-Paul SA, Saura C. et al.
Neratinib + fulvestrant for HER-mutant HR-positive metastatic breast cancer: Updated results from the phase 2 SUMMIT trial.
San Antonio Breast Cancer Symposium 2018; PD3-06
DOI: 10.1158/1538-7445.SABCS18-PD3-06.
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.